Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
0.2894
-0.0205 (-6.62%)
At close: Apr 23, 2026, 4:00 PM EDT
0.271757
-0.0176 (-6.10%)
After-hours: Apr 23, 2026, 7:47 PM EDT
Aditxt Employees
Aditxt had 26 employees as of December 31, 2024. The number of employees decreased by 21 or -44.68% compared to the previous year.
Employees
26
Change (1Y)
-21
Growth (1Y)
-44.68%
Revenue / Employee
$123
Profits / Employee
-$1,657,748
Market Cap
261.75K
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 26 | -21 | -44.68% |
| Dec 31, 2023 | 47 | -14 | -22.95% |
| Dec 31, 2022 | 61 | 3 | 5.17% |
| Dec 31, 2021 | 58 | 15 | 34.88% |
| Dec 31, 2020 | 43 | 41 | 2,050.00% |
| Mar 31, 2020 | 2 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 36 |
| Scinai Immunotherapeutics | 31 |
| Calidi Biotherapeutics | 29 |
| BiomX | 20 |
| CNS Pharmaceuticals | 5 |
| Adial Pharmaceuticals | 5 |
| Onconetix | 2 |
| Propanc Biopharma | 2 |
ADTX News
- 3 days ago - Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients - Business Wire
- 5 weeks ago - Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer - Business Wire
- 5 weeks ago - Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection - Business Wire
- 7 weeks ago - Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026 - Business Wire
- 5 months ago - Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing - Business Wire
- 6 months ago - Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025 - Business Wire
- 6 months ago - Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market - Business Wire
- 6 months ago - Evofem Announces Voting Results from Special Meeting of Stockholders - PRNewsWire